Floatz logo

Ifinatamab Deruxtecan

Malignant Solid Tumor

Daiichi Sankyoantibody_drug_conjugatePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Malignant Solid Tumor cohort.

Asset / SponsorPhaseRating
Nivolumab
Bristol-Myers Squibb
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Genmab
Phase 2B
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Eli Lilly and Company
Phase 2B
(+)-VINCRISTINE
Tianjin Medical University Cancer Institute and Hospital
Phase 2B

View all 50 →

Same molecule, other indications

Ifinatamab Deruxtecan is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
Recurrent or Metastatic Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →